Cue Biopharma Inc reports results for the quarter ended in January - Earnings Summary

Cue Biopharma

09/05/2024 23:04

* Cue Biopharma Inc  CUE.OQ  reported a quarterly adjusted
loss
of 25 cents​​ per share for the quarter ended in January, higher
than the same quarter last year, when the company reported EPS
of -29 cents.  The mean expectation of five analysts for the
quarter was for a loss of 28 cents per share. Wall Street
expected results to range from -32 cents to -24 cents per share.
    * Revenue rose 818.2% to $1.72 million from a year ago;
analysts
expected $1.21 million. 
    * Cue Biopharma Inc's reported EPS for the quarter was a
loss
of 25 cents​.
    * The company reported a quarterly loss of $12.35 million.
    * Cue Biopharma Inc shares had risen by 1.1% this
quarter and
lost 27.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 8.5%
in the last three months.​ 
    * In the last 30 days, two analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Cue Biopharma Inc
is $8.00 
This summary was machine generated from LSEG data May 9 at 10:04
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.28          -0.25          Beat
 Dec. 31 2023      -0.28          -0.29          Missed
 Sep. 30 2023      -0.34          -0.24          Beat
 Jun. 30 2023      -0.30          -0.29          Beat